David C. Oxley

Director/Miembro de la Junta en TB Biosciences, Inc. .

Health Technology

Health Services

Perfil

David C.
Oxley is currently a Non-Executive Director at TB Biosciences, Inc. He previously held the position of Executive VP-Worldwide Sales & Marketing at Trinity Biotech Plc and Vice President-Emerging Market Sales at Plus Therapeutics, Inc. He will also serve as the President-International at Exopharm Ltd.
from 2021 to 2023.

Cargos activos de David C. Oxley

Empresas	Cargo	Inicio
TB Biosciences, Inc. TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA.	Director/Miembro de la Junta	01/08/2013

Todos los cargos activos de David C. Oxley

Antiguos cargos conocidos de David C. Oxley.

Empresas	Cargo	Fin
EXOPHARM	Presidente	01/01/2023
TRINITY BIOTECH PLC	Ventas & Marketing	-
PLUS THERAPEUTICS, INC.	Ventas & Marketing	-

Ver el detalle de la experiencia de David C. Oxley.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de David C. Oxley.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
PLUS THERAPEUTICS, INC.	Health Technology
TRINITY BIOTECH PLC	Health Technology

Empresas privadas	2
TB Biosciences, Inc. TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA.	Health Services
Exopharm Ltd. Exopharm Ltd. Pharmaceuticals: MajorHealth Technology Exopharm Ltd. engages in the research and development of biopharmaceutical drugs. The company was founded by Ian Dixon and Gregor Lichtfuss in 2013 and is headquartered in Camberwell, Australia.	Health Technology